Concerns regarding the recommendation against prescribing selective serotonin reuptake inhibitors in the Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder
- PMID: 38499302
- PMCID: PMC10948180
- DOI: 10.1503/cmaj.149917-l
Concerns regarding the recommendation against prescribing selective serotonin reuptake inhibitors in the Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder
Conflict of interest statement
Competing interests:: Anees Bahji is supported by the Canadian Institutes of Health Research (CIHR), the University of Calgary, and the Calgary Health Trust. He also reports consulting fees from the City of Calgary, honoraria from TED-Ed, and travel grants from the Canadian Psychiatric Association (CPA), the Canadian Society of Addiction Medicine, the American Psychiatric Association, and the American Society of Addiction Medicine. He is an associate editor with the Canadian Journal of Addiction, board member with the International Society of Addiction Journal Editors, and co-chair of the Section of Addiction Psychiatry with the CPA. Marlon Danilewitz reports personal fees for advisory board participation, speaker fees, consulting fees, or education grants from Eisai, Otsuka, Janssen, Lundbeck, Winterlight Labs, Rapids Health, Pearls for Primary Care, the BC Psychiatric Association, and the Ontario Brain Institute. He receives a stipend from the CPA for administrative work and has received support for academic meeting attendance and presentations from Ontario Shores Centre for Mental Health Sciences, the Canadian Academy of Addiction Psychiatry, and the CPA. Matthew Sloan receives funding from the CIHR, the Ontario Ministry of Health and Long-Term Care, Health Canada, the Centre for Addiction and Mental Health Discovery Fund, and the Department of Psychiatry, University of Toronto. He reports honoraria from McGill University Health Centre and travel awards from the Society of Biological Psychiatry and the International Society for Central Nervous System Clinical Trials and Methodology. No other competing interests were declared.
Comment in
-
Addressing the risks of antidepressants among people with alcohol use disorders.CMAJ. 2024 Mar 17;196(10):E349-E350. doi: 10.1503/cmaj.150095-l. CMAJ. 2024. PMID: 38499304 Free PMC article. No abstract available.
Comment on
-
Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.CMAJ. 2023 Oct 16;195(40):E1364-E1379. doi: 10.1503/cmaj.230715. CMAJ. 2023. PMID: 37844924 Free PMC article.
References
-
- Charney DA, Heath LM, Zikos E, et al. Poorer drinking outcomes with citalopram treatment for alcohol dependence: a randomized, double-blind, placebo-controlled Trial. Alcohol Clin Exp Res 2015;39:1756–65. - PubMed
-
- Pettinati HM, Volpicelli JR, Kranzler HR, et al. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000;24:1041–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical